News and Announcements
OncoSil Medical Interview on CE Mark and Growth Plans
- Published November 26, 2015 12:31PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
26th November 2015, ASX Announcement
OncoSil Medical Limited (ASX:OSL) (OncoSil Medical, the Company) is pleased to provide details of an interview with Chief Executive Officer and Managing Director Daniel Kenny and Finance News Network to discuss the Company’s CE Mark progress and growth plans.
The interview can be viewed via the OncoSil Medical company website; via this link: Media interview on CE Mark and Growth Plans
OncoSil Medical is focused on the commercialisation of its lead product candidate, the OncoSilTM localised radiation treatment for cancer. It is concurrently seeking a Conformité Européenne (CE) Mark for OncoSilTM for pancreatic and primary liver cancer (HCC), which would facilitate commercialisation in the European Union and other major markets (including Australia, Canada and Singapore), and US approval via the US FDA.
The Company was granted a Fast Track review for its CE Mark with the European regulator in October this year and expects to receive the outcome of its CE Mark application in the near future.
To read the full announcement, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
